---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005014"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:32:16.696808+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma reports preliminary Q4 2024 neffy revenue of $6.5M, cash $314M

## Summary
- Preliminary neffy net product revenue for Q4 2024 was approximately $6.5 million, total 2024 revenue $7.1 million since launch on Sept 23.
- Cash, cash equivalents and short-term investments were $314.0 million as of Dec 31, 2024, sufficient for at least three years.
- More than 14,500 neffy two-pack units delivered in Q4 2024; over 3,000 healthcare providers prescribed neffy to date.
- Express Scripts added neffy to commercial formularies in Nov 2024; targeting over 80% commercial coverage by Q3 2025.
- sNDA for neffy 1 mg (children 15-30 kg) has PDUFA date March 6, 2025; launch expected Q2 2025 if approved.

## SEC filing metadata
- accession: 0001193125-25-005014
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/0001193125-25-005014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312525005014/d910559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005014
- JSON: https://secwatch.observer/filing/0001193125-25-005014.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.